Oryzon Genomics SA (ES:ORY) has released an update.
Oryzon Genomics S.A. has revealed promising final data from its Phase IIb PORTICO trial evaluating vafidemstat for Borderline Personality Disorder at the ECNP congress. The study showed significant improvements in anger and disease severity measures, and discussions with the FDA for a Phase III study are underway. The results indicate vafidemstat’s potential as an effective treatment option for BPD patients.
For further insights into ES:ORY stock, check out TipRanks’ Stock Analysis page.
